Investors increase stakes in Bain-backed biotech startup as FDA gene‑therapy chief departs

Investors are putting more money into a biotech startup backed by private‑equity firm Bain Capital, according to the STAT+ newsletter.

Vijay Kumar is leaving his role as acting director of the FDA’s Office of Cellular and Gene Therapy, the agency’s top gene‑therapy regulator.

The article also notes that the Trump administration is pursuing a policy to reduce the price of GLP‑1 obesity drugs.

Abivax released additional data on its experimental ulcerative colitis candidate, which appears to address earlier safety concerns.